口山酮的心血管药理作用研究进展

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (11): 1304-1308.

口山酮的心血管药理作用研究进展

刘思妤¹, 石瑞正², 范若皓³, 姜德建¹

¹中南大学药学院药理学系,²湘雅医院心内科,³湘雅医学院临床医学八年制, 长沙 410078, 湖南

收稿日期:2008-03-10 修回日期:2008-10-13 出版日期:2008-11-26 发布日期:2020-10-14
通讯作者: 姜德建,男, 博士/博士后, 副研究员, 硕士生导师, 主要从事心血管疾病的药物防治研究。E-mail: de-jianjiang@mail.csu.edu.cn
作者简介:刘思妤, 女, 硕士研究生, 主要从事天然产物的药理活性研究。
基金资助:
湖南省自然科学基金项目(02jjy2046和06jj3012)

Advancement of pharmacological effects of xanthones in the cardiovascular system

LIU Si-yu¹, SHI Rui-zheng², FAN Ruo-hao³, JIANG De-jian¹

¹Department of Pharmacology, School of Pharmaceutical Sciences,²Department of Cardilogy, Xiangya Hospitol,³Clinical Medicial Student of 8-year Program, Xiangya School of Medicine, Central South University, Changsha 410078, Hunan, China

Received:2008-03-10 Revised:2008-10-13 Online:2008-11-26 Published:2020-10-14

摘要/Abstract

摘要： 天然多酚类化合物口山酮及其衍生物具有广泛的生物学和药理学活性。最近研究发现, 口山酮在多种心血管疾病中发挥保护作用, 其中包括:缺血性心脏病, 动脉粥样硬化, 高血压和血栓性疾病。口山酮的心血管保护作用机制主要涉及抗氧化, 抗炎, 保护血管内皮功能, 抑制血小板聚集, 抗凝血以及舒血管效应。

关键词: 口山酮, 药理, 心血管疾病

Abstract: Xanthones are a class of polyphenolic compounds that commonly occur in plants and have been shown to have extensive biological and pharmacological activities. Recently, the pharmacological properties of xanthone derivatives have been shown to have beneficial effects on some cardiovascular diseases, including ischemic heart disease, atherosclerosis, hypertension and thrombosis. The protective effects of xanthones in the cardiovascular system may be due to their antioxidant, anti-inflammatory, endothelial protective, platelet aggregation inhibitory, antithrombotic and vasorelaxant activities.

Key words: xanthone, pharmacology, cardiovascular disease

中图分类号:

R969

刘思妤, 石瑞正, 范若皓, 姜德建. 口山酮的心血管药理作用研究进展[J]. 中国临床药理学与治疗学, 2008, 13(11): 1304-1308.

LIU Si-yu, SHI Rui-zheng, FAN Ruo-hao, JIANG De-jian. Advancement of pharmacological effects of xanthones in the cardiovascular system[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(11): 1304-1308.

参考文献

[1] Jiang DJ, Tan GS, Ye F, et al. Protective effects of xanthones against myocardial ischemia-reperfusion injury in rats[J]. Acta Pharmacol Sin, 2003, 24(2): 175-180.
[2] Jiang DJ, Tan GS, Zhou ZH, et al. Protective effects of demethylbellidifolin on myocardial ischemia-reperfusion injury in rats[J]. Planta Med, 2002, 68(8): 710-713.
[3] Muruganandan S, Gupta S, Kataria M, et al. Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats[J]. Toxicology, 2002, 176(3): 165-173.
[4] Shen JG, Quo XS, Jiang B, et al. Chinonin, a novel drug against cardiomyocyte apoptosis induced by hypoxia and reoxygenation[J]. Biochim Biophys Acta, 2000, 1500(2): 217-226.
[5] Zhao B, Shen J, Li M, et al. Scavenging effect of Chinonin on NO and oxygen free radicals and its protective effect on the myocardium from the injury of ischemia-reperfusion[J]. Biochim Biophys Acta, 1996, 1315(2): 131-137.
[6] Leiro JM, Alvarez E, Arranz JA, et al. In vitro effects of mangiferin on superoxide concentrations and expression of the inducible nitric oxide synthase, tumour necrosis factoralpha and transforming growth factor-beta genes[J]. Biochem Pharmacol, 2003, 65(8): 1361-1371.
[7] Chiang YM, Kuo YH, Oota S, et al. Xanthones and Benzophenones from the Stems of Garcinia multiflora[J]. J Nat Prod, 2003, 66(8): 1070-1073.
[8] Jiang DJ, Jiang JL, Tan GS, et al. Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine[J]. N-S Arch Pharmacol, 2003, 367(6): 600-606.
[9] Lee HZ, Lin WC, Yeh FT, et al. Decreased protein kinase C activation mediates inhibitory effect of norathyriol on serotonin-mediated endothelial permeability[J]. Eur J Pharmacol, 1998, 353(2 3): 303-313.
[10] Madan B, Singh I, Kumar A, et al. Xanthones as inhibitors of microsomal lipid peroxidation and TNF-alpha induced ICAM-1 expression on human umbilical vein endothelial cells (HUVECs)[J]. Bioorg Med Chem, 2002, 10(11): 3431-3436.
[11] Dai Z, Jiang DJ, Hu GY, et al. 3, 4, 5, 6-tetrahydroxyxanthone protects against myocardial ischemia-reperfusion injury in rats[J]. Cardiovasc Drug Ther, 2004, 18(4): 279-288.
[12] 贾素洁, 李元建. 口山酮对高胆固醇血症大鼠血脂的影响[J]. 中国动脉硬化杂志, 2005, 13(3): 317-319.
[13] 肖红波, 李年生, 贾素洁, 等. 3, 4, 5, 6-四羟基口山酮抑制ApoE-基因缺陷小鼠动脉粥样硬化形成及机制[J]. 国际病理科学与临床杂志, 2006, 26(3): 185-189.
[14] Jiang DJ, Jiang JL, Zhu HQ, et al. Demethylbellidifolin preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level[J]. J Ethnopharmacol, 2004, 93(2/3): 295-306.
[15] Jiang DJ, Hu GY, Jiang JL, et al. Relationship between protective effect of xanthone on endothelial cells and endogenous nitric oxide synthase inhibitors[J]. Bioorg Med Chem, 2003, 11(23): 5171-5177.
[16] Jiang DJ, Jiang JL, Tan GS, et al. Demethylbellidifolin inhibits adhesion of monocytes to endothelial cells via reduction of endogenous nitric oxide synthase inhibitor level[J]. Planta Med, 2003, 69(12): 1150-1152.
[17] Leiro JM, Alvarez E, Arranz JA, et al. In vitro effects of mangiferin on superoxide concentrations and expression of the inducible nitric oxide synthase, tumour necrosis factoralpha and transforming growth factor-beta genes[J]. Biochem Pharmacol, 2003, 65(8): 1361-1371.
[18] 姜德建, 李元建. 非对称性二甲基精氨酸—新的心血管疾病危险因子和药物防治靶点[J]. 中国动脉硬化杂志, 2005, 13(3): 379-382.
[19] Chericoni S, Testai L, Calderone V, et al. The Xanthones gentiacaulein and gentiakochianin are responsible for the vasodilator action of the roots of Gentiana kochiana[J]. Planta Med, 2003, 69(8): 770-772.
[20] Wang LW, Kang JJ, Chen IJ, et al. Antihypertensive and vasorelaxing activities of synthetic xanthone derivatives[J]. Bioorg Med Chem, 2002, 10(3): 567-572.
[21] Wang Y, Shi JG, Wang MZ, et al. Mechanisms of the vasorelaxant effect of 1-hydroxy-2, 3, 5-trimethoxy-xanthone, isolated from a Tibetan herb, Halenia elliptica, on rat coronary artery[J]. Life Sciences, 2007, 81(12): 1016-1023.
[22] Rajtar G, Zolkowska D, Kleinrok Z, et al. Antiplatelets activity of some xanthone derivatives[J]. Acta Pol Pharm, 1999, 56(4): 319-324.
[23] Lin CN, Liou SS, Ko FN, et al. Gamma-pyrone compounds. II: Synthesis and antiplatelet effects of tetraoxygenated xanthones[J]. J Pharm Sci, 1992, 81(11): 1109-1112.
[24] Jantan I, Pisar MM, Idris MS, et al. In vitro inhibitory effect of rubraxanthone isolated from Garcinia parvifolia on platelet-activating factor receptor binding[J]. Planta Med, 2002, 68(12): 1133-1134.
[25] Ishiguro K, Nagata S, Oku H, et al. Bisxanthones from Hypericum japonicum:inhibitors of PAF-induced hypotension[J]. Planta Med, 2002, 68(3): 258-261.